NAYA Biosciences Inc. (NAYA): Forward Price-to-Revenue Multiple
NAYA Biosciences is enhancing its scientific image by integrating reproductive medicine with oncology. High R&D expenditures and stringent FDA oversight create significant barriers to entry for competitors. The closed nature of the biotech ecosystem through clinical phases stabilizes the base. The GURU.Markets system generates this chart, where the forward P/S ratio reflects valuation dynamics, and the indicator value reaches 0.30, signaling risks of asset overvaluation.
NAYA Biosciences Corp (NAYA) - metric breakdowns and financial figures
- current price and projected stock value:
- stock exchange capitalization data:
- business book valuation details:
- debt and liquidity data:
Total Debt to Capital NAYA Biosciences|NAYA - Long-Term Debt to Equity|Short-Term Debt to Capital NAYA Biosciences|NAYA - Company Total Debt Obligations|Debt to Book Capitalization Ratio NAYA Biosciences Corp|NAYA - Long-Term Debt|Company Short-Term Debt NAYA Biosciences|Quick Ratio nayabiosciences.com
- financial results and valuation multiples details:
NAYA - Net Income|Projected Future Earnings NAYA Biosciences|NAYA - Business Payback Period|Forward P/E Multiple NAYA Bio|NAYA - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NAYA Biosciences Corp|NAYA - Operating profit before amortization|Net earnings per share (EPS TTM) NAYA Biosciences|NAYA - Net earnings per share for the last 12 months|Quarterly EPS earnings growth nayabiosciences.com|NAYA - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year NAYA Biosciences
- total revenue and sales volume data:
Comprehensive company analysis:NAYA (NAYA Biosciences Inc.)
This metric is calculated as the ratio of current market capitalization to projected revenue, allowing for an objective valuation of the asset relative to future cash flows. By analyzing the expected P/S ratio, an investor can align market expectations with the intensive R&D cycle of NAYA Biosciences (NAYA) focused on developing bispecific antibodies, determining a fair balance between the share price and the success of clinical drug validation.
Competitor analysis
Forward P/S Multiple ONC (BeiGene)|Forward P/S Multiple Halozyme Therapeutics, Inc. HALO|RVMD: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Ascentage Pharma Corp|CGON: Forward P/S Multiple|urogen.com (URGN) - Forward P/S Multiple|Forward Price-to-Revenue Multiple BCAX|PSNL: Forward Price to Sales|Forward P/S Multiple ERAS|Price-to-Projected Revenue Ratio DCTH (Delcath Corp)|Forward P/S Multiple YMAB (Y-mAbs Therapeutics)|Market Cap to Expected Sales Ratio aurabiosciences.com (AURA)|CADL - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Accuray Inc|sellaslifesciences.com (SLS) - Price-to-Projected Revenue Ratio|ACTU - Market Cap to Expected Sales Ratio|CTOR (Citius Oncology, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TuHURA (HURA)|Forward P/S Multiple TARA|Market Cap to Expected Sales Ratio Fate Therapeutics Inc|Forward P/S Multiple WHWK (Aadi Bioscience)|TScan Therapeutics Inc (TCRX) - Market Cap to Future Revenue Ratio|CSBR - Price-to-Projected Revenue Ratio|XBIT (XBiotech Inc.) - Market Cap to Projected Revenue|CVM: Forward P/S Multiple|Forward Price-to-Revenue Multiple OS Therapies Inc.|RADX (Radiopharm Theranostics Limited) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Artiva ARTV|Price-to-Projected Revenue Ratio Adlai Nortye Ltd. (ANL)|Market Cap to Expected Sales Ratio verupharma.com|Price-to-Projected Revenue Ratio Tempest Therapeutics, Inc. TPST|XLO: Market Cap to Projected Revenue|Enochian BioSciences - Forward P/S Multiple|MURA - Forward P/S Multiple|KAPA (kairospharma.com) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio OnKure Therapeutics (OKUR)|GDTC (CytoMed Therapeutics Ltd) - Forward P/S Multiple|Forward P/S Multiple Curis Corp|Forward P/S Multiple APLM|Forward Price-to-Revenue Multiple Tharimmune Corporation THAR|Forward P/S Multiple ADVB (Advanced Biomed)|Forward P/S Multiple genprex.com GNPX|CLDI - Price-to-Projected Revenue Ratio|SBFM (Sunshine Biopharma Inc.) - Market Cap to Projected Revenue|XBIO: Forward P/S Multiple|Forward Price-to-Revenue Multiple Salarius Pharma|PPBT (Purple Biotech) - Forward P/S Multiple|Market Cap to Future Revenue Ratio AON AONC|Price-to-Projected Revenue Ratio BeiGene (BGNE)|CKPT (Checkpoint Therapeutics Inc.) - Forward Price to Sales|Elevation Oncology, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales ICAD|Ikena - Forward P/S Multiple|notablelabs.com (NTBL) - Forward Price-to-Revenue Multiple|VIRX (viracta.com) - Forward Price-to-Revenue Multiple|MorphoSys Inc (MOR) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Ascentage Pharma Group Ltd
